Researchers tested whether adding activated charcoal to the standard gout medication febuxostat would help people with gout. They studied 348 patients with primary gout over 24 weeks, comparing different doses of the combination treatment against febuxostat alone.
The combination treatment did not work better than febuxostat alone at lowering urate levels in the blood, which is the main goal of gout treatment. However, patients taking the combination had fewer painful gout flares, experienced their first flare later, and had lower cholesterol levels at the end of the study.
Safety appeared similar across all treatment groups, though the study didn't report details about serious side effects or why people might stop treatment. The main reason to be careful is that reducing flares and cholesterol were secondary goals of the study, while the primary goal of lowering urate wasn't improved.
Readers should understand this is one study showing a possible benefit for reducing flares, but it didn't improve the main treatment target. People with gout should talk with their doctor about their treatment options rather than making changes based on this single study.